SG163545A1 - 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses - Google Patents

3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Info

Publication number
SG163545A1
SG163545A1 SG201004695-1A SG2010046951A SG163545A1 SG 163545 A1 SG163545 A1 SG 163545A1 SG 2010046951 A SG2010046951 A SG 2010046951A SG 163545 A1 SG163545 A1 SG 163545A1
Authority
SG
Singapore
Prior art keywords
treatment
compound
substituted
synaptic responses
glutamatergic synaptic
Prior art date
Application number
SG201004695-1A
Other languages
English (en)
Inventor
Alexis Cordi
Gary Rogers
Rudolf Mueller
Original Assignee
Servier Lab
Cortex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Cortex Pharma Inc filed Critical Servier Lab
Publication of SG163545A1 publication Critical patent/SG163545A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG201004695-1A 2007-01-03 2007-12-28 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses SG163545A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87850307P 2007-01-03 2007-01-03
US92143307P 2007-04-02 2007-04-02

Publications (1)

Publication Number Publication Date
SG163545A1 true SG163545A1 (en) 2010-08-30

Family

ID=39608956

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201004695-1A SG163545A1 (en) 2007-01-03 2007-12-28 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Country Status (38)

Country Link
US (1) US8173644B2 (es)
EP (1) EP2144506B1 (es)
JP (1) JP5139446B2 (es)
CN (1) CN101616592B (es)
AP (1) AP2502A (es)
AR (1) AR064740A1 (es)
AT (1) ATE527269T1 (es)
AU (1) AU2007342365B2 (es)
BR (1) BRPI0720749A2 (es)
CA (1) CA2674460C (es)
CR (1) CR10906A (es)
CU (1) CU23804B7 (es)
CY (1) CY1112493T1 (es)
DK (1) DK2144506T3 (es)
EA (1) EA017437B1 (es)
EC (1) ECSP099499A (es)
ES (1) ES2374995T3 (es)
GE (1) GEP20125438B (es)
GT (1) GT200900189A (es)
HK (1) HK1140105A1 (es)
HN (1) HN2009001268A (es)
HR (1) HRP20110970T1 (es)
IL (1) IL199651A (es)
MA (1) MA31160B1 (es)
ME (1) ME00819B (es)
MX (1) MX2009007242A (es)
MY (1) MY154877A (es)
NI (1) NI200900131A (es)
NZ (1) NZ578293A (es)
PL (1) PL2144506T3 (es)
PT (1) PT2144506E (es)
RS (1) RS52108B (es)
SG (1) SG163545A1 (es)
SI (1) SI2144506T1 (es)
SV (1) SV2009003322A (es)
TN (1) TN2009000277A1 (es)
WO (1) WO2008085506A1 (es)
ZA (1) ZA200904826B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009007209A (es) * 2007-01-03 2009-10-12 Cortex Pharma Inc Compuestos de [1, 2, 3]-benzotriazinona-sustituidos en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas.
KR101599661B1 (ko) 2007-05-17 2016-03-03 코텍스 파마슈티칼스, 인크. 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 이치환된 아미드 화합물
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8263591B2 (en) 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
EP2784065B1 (en) 2011-11-22 2016-10-05 Beijing Medisan Technology Co. Ltd. Glycine reuptake inhibitor and use thereof
FR3019464B1 (fr) * 2014-04-07 2016-05-06 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
FR3034019B1 (fr) 2015-03-26 2017-03-17 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
EP3313836B1 (en) 2015-06-26 2020-11-11 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
CN106226509B (zh) * 2016-08-12 2019-09-06 中国人民解放军第四军医大学 一种在小鼠前扣带回皮层诱发dse现象的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723436A (en) * 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FR2597103B1 (fr) * 1986-04-15 1988-12-16 Provesan Sa Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
CA2450801C (en) * 1992-07-24 2009-11-17 The Regent Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
DK0709384T3 (da) * 1994-10-31 1999-08-23 Merck Patent Gmbh Benzylpiperidinderivater med høj affinitet til aminosyrereceptorers bindingssteder
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
AU4416197A (en) * 1996-09-17 1998-04-14 Regents Of The University Of California, The Positive ampa receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
EE200000468A (et) 1998-02-18 2002-04-15 Neurosearch A/S Ühendid, nende kasutamine ja farmatseutiline kompositsioon
US6713474B2 (en) * 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones
PL371722A1 (en) * 2001-11-26 2005-06-27 Cortex Pharmaceuticals, Inc. Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
JP2003238555A (ja) * 2002-02-20 2003-08-27 Sumitomo Pharmaceut Co Ltd 細胞死抑制剤
AUPS255202A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
US20060276462A1 (en) * 2003-01-13 2006-12-07 Deadwyler Sam A Method of treating cognitive decline due to sleep deprivation and stress
GB0317482D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
MX2009007209A (es) * 2007-01-03 2009-10-12 Cortex Pharma Inc Compuestos de [1, 2, 3]-benzotriazinona-sustituidos en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas.
KR101599661B1 (ko) * 2007-05-17 2016-03-03 코텍스 파마슈티칼스, 인크. 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 이치환된 아미드 화합물
US8263591B2 (en) 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
NZ584098A (en) * 2007-09-20 2012-05-25 Cortex Pharma Inc 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses

Also Published As

Publication number Publication date
EA017437B1 (ru) 2012-12-28
ATE527269T1 (de) 2011-10-15
PL2144506T3 (pl) 2012-04-30
ECSP099499A (es) 2009-10-30
CA2674460A1 (en) 2008-07-17
CR10906A (es) 2009-10-23
EP2144506B1 (en) 2011-10-05
SI2144506T1 (sl) 2012-01-31
CU23804B7 (es) 2012-03-15
SV2009003322A (es) 2010-02-05
ME00819B (me) 2012-03-20
CN101616592B (zh) 2013-06-05
NI200900131A (es) 2010-03-11
JP2010514838A (ja) 2010-05-06
JP5139446B2 (ja) 2013-02-06
IL199651A (en) 2015-08-31
MY154877A (en) 2015-08-14
MX2009007242A (es) 2009-09-02
US20100137295A1 (en) 2010-06-03
TN2009000277A1 (en) 2010-10-18
ES2374995T3 (es) 2012-02-23
AR064740A1 (es) 2009-04-22
AU2007342365B2 (en) 2012-11-15
EP2144506A4 (en) 2010-05-05
WO2008085506A1 (en) 2008-07-17
IL199651A0 (en) 2010-04-15
HN2009001268A (es) 2011-12-27
RS52108B (en) 2012-08-31
CY1112493T1 (el) 2015-12-09
EP2144506A1 (en) 2010-01-20
CN101616592A (zh) 2009-12-30
CU20090117A7 (es) 2011-10-05
EA200900925A1 (ru) 2009-12-30
US8173644B2 (en) 2012-05-08
MA31160B1 (fr) 2010-02-01
GT200900189A (es) 2011-08-02
GEP20125438B (en) 2012-03-26
HK1140105A1 (en) 2010-10-08
ZA200904826B (en) 2010-09-29
HRP20110970T1 (hr) 2012-01-31
BRPI0720749A2 (pt) 2014-01-14
NZ578293A (en) 2012-01-12
AP2009004931A0 (en) 2009-08-31
DK2144506T3 (da) 2012-03-05
PT2144506E (pt) 2011-12-21
CA2674460C (en) 2014-07-15
AU2007342365A1 (en) 2008-07-17
AP2502A (en) 2012-10-23

Similar Documents

Publication Publication Date Title
SG163545A1 (en) 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
TN2009000278A1 (en) 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
EA201390971A1 (ru) ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
BRPI0817271A2 (pt) Método de tratamento da doença de parkinson e outros distúrbios relacionados
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
WO2008050341A3 (en) Novel psychotropic agents having glutamate nmda activity
WO2008148801A8 (en) Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
MX2010001824A (es) Heterociclos como moduladores de canal de potasio.
EP2977452A3 (en) Methods of treatment and prevention of neurodegenerative diseases and disorders
WO2012040727A3 (en) Methods for diagnosis and treatment of neurodegenerative diseases or disorders
WO2013029060A3 (en) Compositions and methods for treating neurodegenerative disease
JP2009537568A5 (es)
WO2003045315A3 (en) Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
WO2008022154A3 (en) Methods of identifying agents for treating neurological disorders
WO2007034326A3 (en) Imidazole compounds for the treatment of neurological disorders
UA93306C2 (ru) Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций
IL196615A0 (en) N-phenyl-prenylamine derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
IL196617A0 (en) Phenyl-prenyl-ether derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
WO2011123842A9 (en) Methods for treating parkinson's disease and other disorders of dopaminergic neurons of the brain
WO2011015646A3 (en) Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
MX2011008060A (es) Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas.
EP4045149A4 (en) REGENERATION OF FUNCTIONAL NEURONS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
TN2011000105A1 (en) Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use